ResearchFuture & Ongoing
We recently started an ongoing cancer registry through an Institutional Review Board approved study at M. D. Anderson Cancer Center. The purpose of the research is to obtain information about diagnosis, stage, treatment and survival of women with this disease.
Phase II Trial of Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC) including High Grade Neuroendocrine Carcinoma of the Cervix
This phase II trial studies the effect of niraparib and dostarlimab in treating high grade neuroendocrine carcinoma of the cervix along with small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab together may help to control the diseases by increasing cancer killing synergistically. All patients enrolled on the trial will get both drugs given at FDA approved doses. No patients will get placebo.
E-mail our team for more information about the trial: email@example.com
We will be conducting a study at M. D. Anderson Cancer Center to test high grade neuroendocrine cervical cancers, including small cell and large cell, for molecular alterations. We recently received Institutional Review Board approval and will be beginning to collect tumors for testing soon. We hope that by identifying some of the mutations that occur in these tumors, we can design future clinical trials that will use appropriately targeted chemotherapy.